Dr Pasi Janne speaks to ecancer about key findings from the final overall survival subgroup analysis of the phase III FLAURA2 trial, evaluating first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC).

The trial showed that combination therapy reduced risk of death by 23% (HR 0.77; p=0.02) compared to monotherapy. Consistent benefit across prognostic subgroups were seen. Furthermore, median overall survival was longer with osimertinib and chemotherapy across all high-risk groups.

Dr Janne highlights that these results reinforce osimertinib plus chemotherapy as the preferred first-line standard of care for EGFR-mutated advanced NSCLC, regardless of high-risk disease features.